# Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

> **NCT03366272** · PHASE2,PHASE3 · COMPLETED · sponsor: **Universität des Saarlandes** · enrollment: 348 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Rituximab
- **DRUG:** Gemcitabine
- **DEVICE:** Oxaliplatin

## Key facts

- **NCT ID:** NCT03366272
- **Lead sponsor:** Universität des Saarlandes
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-05
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03366272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03366272, "Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03366272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*